Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Solomon

Showing results (361-370 of 1,211) with videos related to

Pageof 122
Sort By:
Circulation|October 7, 2004
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programScott D Solomon, Duolao Wang, Peter Finn, et al.
Heart Rhythm|May 29, 2013
Atrioventricular delay programming and the benefit of cardiac resynchronization therapy in MADIT-CRTAndrew Brenyo, Valentina Kutyifa, Arthur J Moss, et al.
European Journal of Heart Failure|May 16, 2014
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)John J V McMurray, Milton Packer, Akshay S Desai, et al.
European Journal of Heart Failure|January 20, 2015
Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trialStephen J Greene, Aldo P Maggioni, Gregg C Fonarow, et al.
Circulation|September 12, 2014
Temporal trends in the population attributable risk for cardiovascular disease: the Atherosclerosis Risk in Communities StudySusan Cheng, Brian Claggett, Andrew W Correia, et al.
European Journal of Heart Failure|February 7, 2015
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fractionAdriaan A Voors, Mauro Gori, Licette C Y Liu, et al.
JACC. Basic to Translational Science|May 28, 2025
Derisking Phase II Clinical Trials in Heart Failure: A Position Paper from JACC: Basic to Translational Science and the Heart Failure CollaboratoryDouglas L Mann, G Michael Felker, Ellis F Unger, et al.
Journal of the American College of Cardiology|August 6, 2025
Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With CardiomyopathyKarola S Jering, Marianna Fontana, Hicham Skali, et al.
Nature Medicine|August 6, 2025
Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trialKarola S Jering, Marianna Fontana, Olivier Lairez, et al.
European Journal of Heart Failure|June 11, 2016
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Milton Packer, et al.
Pageof 122

Showing results (361-370 of 1,211) with videos related to

Sort By:
Pageof 122
Circulation|October 7, 2004
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programScott D Solomon, Duolao Wang, Peter Finn, et al.
Heart Rhythm|May 29, 2013
Atrioventricular delay programming and the benefit of cardiac resynchronization therapy in MADIT-CRTAndrew Brenyo, Valentina Kutyifa, Arthur J Moss, et al.
European Journal of Heart Failure|May 16, 2014
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)John J V McMurray, Milton Packer, Akshay S Desai, et al.
European Journal of Heart Failure|January 20, 2015
Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trialStephen J Greene, Aldo P Maggioni, Gregg C Fonarow, et al.
Circulation|September 12, 2014
Temporal trends in the population attributable risk for cardiovascular disease: the Atherosclerosis Risk in Communities StudySusan Cheng, Brian Claggett, Andrew W Correia, et al.
European Journal of Heart Failure|February 7, 2015
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fractionAdriaan A Voors, Mauro Gori, Licette C Y Liu, et al.
JACC. Basic to Translational Science|May 28, 2025
Derisking Phase II Clinical Trials in Heart Failure: A Position Paper from JACC: Basic to Translational Science and the Heart Failure CollaboratoryDouglas L Mann, G Michael Felker, Ellis F Unger, et al.
Journal of the American College of Cardiology|August 6, 2025
Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With CardiomyopathyKarola S Jering, Marianna Fontana, Hicham Skali, et al.
Nature Medicine|August 6, 2025
Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trialKarola S Jering, Marianna Fontana, Olivier Lairez, et al.
European Journal of Heart Failure|June 11, 2016
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Milton Packer, et al.
Pageof 122